

1 best way to do it, is build it into the office visits as
2 far as time.

3 MR. CHAPPELL: Should I assume that Medicare
4 and Medicaid are standards, in your opinion, for
5 reimbursement?

6 DR. KAIL: Well, I think that is a standard of
7 acceptance.

8 MR. CHAPPELL: That is my real question. Are
9 we looking for credibility or economic sustainability?

10 DR. KAIL: I think the credibilities may come
11 more from the research side. I think the economic
12 stability is going to come from the reimbursement side,
13 but you don't get one without the other is the problem,
14 and I think that inclusionary language will allow more
15 people to come forward, so that insurance companies can
16 get better data.

17 Right now, for instance, some of the insurance
18 companies that have been reimbursing are not reimbursing
19 for certain programs anymore. I can give you one
20 example. There was a program that put a cost of \$7.00
21 per member per month for reimbursement for alternative
22 services. That was not well advertised, and even though

1 there was a cohort of people that had access to this care
2 that were seniors, because it was poorly advertised to
3 the seniors and because it was such a great expense and
4 not well sold to the buyers, it was an underused program
5 that was not continued because of lack of use.

6 Well, had that been a different thing where it
7 would have been more like 50 cents per member per month,
8 which some plans have advocated, and it was well sold to
9 the people that were buying it, the employers, et cetera,
10 they would have had a better outcome and they would have
11 continued that longer, and they would have had better
12 statistics to use for their own utilization statistics.

13 That is proprietary information. There are
14 granting mechanisms that the NIH have come up with now,
15 that hopefully, actuaries and other people will allow a
16 pool of information to stay in a non-proprietary fashion
17 where we can get those utilization statistics out, but
18 reimbursement is not going to come until there is better
19 figures on utilization, and I think forcing that a little
20 bit by inclusionary language in Medicare and Medicaid is
21 the fastest way to get that to come forward.

22 DR. GORDON: Thank you.

1 Bill.

2 DR. FAIR: My background has been entirely,
3 professional background, entirely in medical schools, so
4 I am interested in education, and I will address this
5 question to Patricia, but it is really a global question
6 to the panel.

7 That is, how do we go about this education?
8 You had mentioned, I believe, that training physicians in
9 acupuncture, clearly, medical school, as jam-packed as it
10 is, we can't train physicians to be acupuncturists and
11 naturopaths and chiropractors and massage therapists, and
12 so forth, so is this education better spent in terms of
13 training medical students and physicians in the
14 effectiveness and perhaps a cost benefit of these things
15 as opposed to delivering the modalities themselves, or
16 just how do we get this training and what kind of
17 training should it be?

18 MS. CULLITON: Well, I agree with the second
19 half of your statement or totally of your statement. No,
20 I do not think that in medical schools we should try to
21 incorporate into medical education that everyone become
22 an acupuncturist and a homeopath, et cetera. It would be

1 impossible, unless we want our physicians to go to school
2 for 20 or 30 years.

3 DR. FAIR: But Andy Weil, for instance, who
4 started this integrated fellowship, that is an example of
5 that type of approach.

6 MS. CULLITON: That is an example, and my
7 division in Minneapolis is an example of a different type
8 of approach where we are actually within the Department
9 of Medicine at an academic institution, but all the
10 providers are non-physician providers. Salaries are
11 significantly less, et cetera, but there is also a wider
12 depth of knowledge of a particular intervention when
13 somebody has studied strictly Chinese medicine for five
14 years.

15 So, my recommendation is that medical education
16 should include overviews of what is out there, clinical
17 and cost effectiveness, appropriate referrals, et cetera,
18 and if physicians have a dream, have a path, I know there
19 is an American Medical Acupuncture Association, and a lot
20 of physicians really have taken very seriously into
21 studying acupuncture.

22 Those options would be available, but that

1 isn't part of the curriculum that I am talking about that
2 I would like to see in medical school education. It
3 would be much more the overview of how to interact,
4 appropriate referrals, those types of things.

5 DR. MEEKER: I agree with you. I think that
6 the time is spent learning about those things with one
7 additional thing, and that is training in
8 interdisciplinary practice. A few health commissions
9 have recommended that interdisciplinary behavior be
10 explicitly taught in medical school, and I think that
11 there is a big need for that.

12 It is difficult now even, and I think with
13 respect to the CAM professions, there is even a greater
14 need to train all health professionals, not just medical
15 doctors, but CAM professionals, as well, in how to
16 interrelate to each other.

17 DR. FAIR: So, you would recommend then that
18 the various modalities under the CAM umbrella, if one
19 could categorize all of them, would be an integral part
20 of the education of medical students and young
21 physicians?

22 DR. MEEKER: Not to the point of actually

1 performing them, but, as you said, to understand them.

2 DR. FAIR: Okay. Again, benefits and efficacy,
3 and so forth.

4 DR. MEEKER: Right.

5 DR. KAIL: I think that distinction needs to be
6 made very clear, though. I think there is a lot of
7 allopathic physicians out there that go and take a couple
8 courses in this and that, and then proceed to practice
9 that without a full appreciation of all the other stuff
10 that goes behind that culture.

11 I think it is very important that we make a big
12 distinction between this is informational, so that you
13 will have an appreciation for this modality and know
14 whether or not you want to recommend it to a patient as
15 opposed to this is the level at which you can start
16 practicing this.

17 Again, I would recommend that if you don't have
18 200 hours of classroom, you probably shouldn't be
19 reimbursed and you probably shouldn't be practicing that
20 modality.

21 DR. FAIR: This is my concern. I think in New
22 York, an M.D., and I may have been off in the numbers,

1 can get a license as an acupuncturist in something like
2 300 hours where it may be 3,000 hours for someone that
3 goes the traditional route. I have no personal
4 experience, but I just can't imagine that you could learn
5 as much in a tenth of the time.

6 DR. FRYE: I see the situation in homeopathy a
7 little differently. We actually have two levels of
8 certification. At this point they are not terribly well
9 established or disseminated, but there is an acute care
10 level, as well as a sort of specialist level, and I think
11 that given that homeopathic medicines are included in the
12 FDA Homeopathic Pharmacopeia, that having at least
13 primary acute level of training in homeopathy in medical
14 school, along with your traditional training in pharmacy
15 or whatever you might use to treat a particular condition
16 is appropriate.

17 Certainly, going to the level of specialist
18 training in medical school would be far too time-
19 consuming, but I think acute level of training is
20 entirely possible.

21 DR. GORDON: Thank you. We are going to have a
22 chance, I think this is a very important issue to come

1 back to this for the education panel.

2 DR. FAIR: I have one question for Tiffany
3 also. What are the barriers to massage in cancer
4 patients, because I hear this a lot from massage
5 therapists and also some physicians, although it is sort
6 of lessening from physicians, but there was a time not
7 too long ago, 20 years ago, when children with abdominal
8 tumors, for instance, they would post signs on the bed,
9 "Do not palpate," and I think this is still imbued in
10 some of the massage therapists' philosophy. Am I
11 correct?

12 DR. FIELD: My understanding currently is that
13 the contraindications are coming from the massage
14 therapists, not from the pediatric oncologists. The
15 argument they make, the massage therapists are saying
16 that basically, they are concerned about metastasis and
17 the spread of cancer by the increase in blood flow and
18 lymph, and so on.

19 DR. FAIR: Is that real or theoretical? I
20 guess that is my question.

21 DR. FIELD: It is certainly not real, it hasn't
22 been tested, but the oncologists will say, well, for the

1 same reason that you are concerned about the cancer being
2 spread, we are concerned about blood flow spreading the
3 immune cells. So, there is still a lot of controversy
4 about that.

5 DR. GORDON: Charlotte.

6 SISTER KERR: I heard important speaking this
7 morning on at least three points, and one was that caring
8 time and listening healed touch was essential to healing,
9 physical, mental, or spiritual, and that it was essential
10 to empower people to heal themselves.

11 Tiffany, I was very edified to hear about your
12 study with the elderly and the babies and to see the
13 mutuality and the healing, and what I wanted to ask you
14 and anyone on the panel is since the role of the prophet
15 is one of imagination, what could you imagine could be
16 done? I am looking specifically at grass-roots level at
17 this moment of public health in your particular area that
18 might have a significant effect within a local community.

19 For example, I could imagine that mothers
20 sharing massage, you know, would decrease postpartum
21 depression and probably a million other things, but a
22 massage co-op, you know, in the community, come in and

1 you borrowed a massage.

2 So, I am wondering -- and it could come from
3 other members of the panel -- is there anything there you
4 could tell me now or, if not now, if you could give it to
5 me later for the panel.

6 DR. FIELD: Well, I would like to say that I
7 think that our elderly are a wasted resource and are
8 beginning to present a lot of problem related to
9 depression and touch deprivation, and so on, to the
10 medical community, and I think that preschools, for
11 example, could use elderly volunteers in a very big way.

12 That would get a lot of touch going. I don't
13 know if you know, but a lot of mandates are out there now
14 that children should not be touched even in preschool
15 because of concern about the legal aspect of sexual
16 abuse, and so on.

17 I can't imagine an elderly person being accused
18 of sexually abusing a preschooler. I mean it is less
19 likely than, say, a young man or something. So, I think
20 that that would be one way to get grass-roots preventive
21 care going for both sides, the elderly and the young
22 people.

1 DR. KAIL: I think partially it is a quality of
2 information problem. A lot of people are doing self-
3 care, as we said, but a lot of it is based on poor
4 quality information that is just in the lay press or
5 especially multilevel marketed stuff. There is a whole
6 lot of bad ideas being put out there by people that are
7 uneducated and a lot of poor recommendations out there by
8 people that have no training.

9 So, I think there needs to be some venue at the
10 community level where people can tap into to get quality
11 information about health care practices whether they be
12 alternative or conventional.

13 DR. MEEKER: One last thing on this area. In
14 terms of prevention and health promotion, wellness care,
15 I think one of the biggest problems in clinical practice
16 is that doctors of all stripes don't get reimbursed for
17 that time, and if there was a way to recommend that
18 billing codes, reimbursement systems, et cetera, would
19 start to recognize that this an important part of
20 clinical practice, that perhaps we could start changing
21 doctors' behavior, that would soon start changing patient
22 behavior, as well, but I think one of the biggest

1 barriers is at the reimbursement level.

2 DR. GORDON: Effie.

3 DR. CHOW: All the discussions that have taken
4 place leading to this sort of more global and visionary
5 question that I have is that we discuss about health
6 promotion and education and teaching self care, and care,
7 and giving time, and all that, is it appropriate to try
8 and look at integrating this into a medical model or in
9 your ideals and your dreams and your goals, what would
10 you see your profession, how does it stand, as separate
11 or integrated in a different way, setting a different
12 parameter or paradigm, or trying to squeeze it into the
13 mold that we have as a health care system?

14 I know you don't have time to answer this, but
15 I certainly would like some written things back, but if
16 you have some comments, I would really appreciate that.

17 DR. KAIL: Just a brief comment. I think that
18 naturopathic medicine is inherently focused on prevention
19 and self-care issue. I think that if there was an
20 opportunity to have those issues addressed first in the
21 medical model, that that would go a long way, whether
22 that be integrating that care somehow by having them come

1 in as gatekeepers, and send them out to other people, I
2 don't know, but I think that some venue where early on in
3 care those issues are addressed at a stronger level than
4 they are now would facilitate the whole process.

5 DR. GORDON: Thank you.

6 Tiffany, are you planning to replicate the
7 study on preemies?

8 DR. FIELD: Well, we have done several
9 replications, and now there are approximately five
10 replications in other parts of the world using the same
11 paradigm.

12 DR. GORDON: Could you give us that data, as
13 well?

14 DR. FIELD: Yes.

15 DR. GORDON: That would be very helpful.

16 Tieraona, I know you want to ask a question.

17 DR. LOW DOG: Real quick. Thank you.

18 I think this is for anybody, but especially for
19 Konrad. In Western medicine now, with the consort
20 statement and a lot of work being done on trying to
21 improve quality trials and trying to improve evidence, we
22 are now looking at taking away many things, we are not

1 paying for as many things, and it is changing the way
2 physicians practice medicine as we move more and more
3 towards evidence-based medicine.

4 While I realize that there is just an absolute
5 shortage of funding for CAM therapies in general, so it
6 puts us in this place of a bind, is it a bit premature,
7 are we putting the cart before the horse a little bit to
8 want to include things that are not yet proven, it
9 doesn't mean they are ineffective, but not yet proven to
10 be reimbursed by an already overburdened system, such as
11 Medicare and Medicaid?

12 DR. KAIL: I think that is the catch-22
13 question to end all catch-22 questions, how can you find
14 out the information without large bodies of people having
15 access to those types of care.

16 I think we are going to have to spend a few
17 dollars to let some at least controlled groups have
18 unlimited access to that care to see what happens.

19 I think you can do that in a controlled
20 fashion, but I think that is going to have to come first,
21 so that a good segment of the population, especially the
22 poor people, I mean there is a perception that is

1 starting to change that it isn't white, Anglo-Saxon,
2 Protestant, higher educated people, but I would like to
3 see some more trials in specific populations, the elderly
4 and the poor folks, small children, et cetera, that come
5 forth.

6 But I think we are going to have to spend some
7 dollars and give some open access to at least a few
8 groups in controlled situations in order to get the data
9 we need to know what to spend more dollars on.

10 DR. MEEKER: I think, Tieraona, that there are
11 issues of equity, too. Chiropractors are not reimbursed
12 in the Medicare system now even though spinal
13 manipulations is one of the most studied forms of care
14 for back pain at least, and is recommended by the U.S.
15 Government, and yet we are treated as third-class
16 citizens in the Medicare system.

17 So, I think what it really comes down to when
18 we are talking about some of the stuff is not whether
19 something needs to be proven or not before it is
20 included, but whether or not the things that are already
21 paid for actually have evidence, as well, and is equity
22 being applied to the entire situation.

1 DR. LOW DOG: I would just like to say be
2 careful of what you wish for because you might get it. I
3 spent about seven or eight years trying to get medical
4 assistance reimbursement for acupuncture in Minnesota,
5 and we have it now, and I am glad that we do, but we get
6 \$12.00 reimbursement, we probably spend \$20.00 on
7 paperwork, and we would go broke if we only had a
8 practice of people receiving medical assistance.

9 It is a wonderful gift to be able to offer that
10 to an expanded community, but I think we have to be
11 cautious in what we ask for.

12 DR. FRYE: I think it is important to us while
13 looking for evidence, too, that we try to avoid doing
14 just the quick and dirty studies that give us, yes, this
15 modality works for this indication, where it is important
16 to do more longitudinal kinds of studies to show whether
17 doing this now actually helps to prevent further disease
18 from developing five or 10 years from now.

19 DR. GORDON: Thank you very much. We are going
20 to break now. I would invite you -- would you send us
21 that information about the \$12.00 reimbursement and
22 \$20.00 paperwork, please?

1 DR. LOW DOG: Sure.

2 DR. GORDON: And anybody else who has examples
3 of that kind. Our charge is to make legislative
4 recommendations, and we want to hear about it.

5 Thank you very much. We are going to take a
6 five-minute break only and then we are going to start the
7 next panel. We are a little behind time.

8 [Recess.]

9 DR. GORDON: We are going to begin with the
10 next panel now. The first speaker will be Dennis Awang.

11 **Herbs/Botanicals**

12 DR. AWANG: I think the Commission for inviting
13 me. I am neither clinician nor an economist, so my
14 contribution to clinical and cost effectiveness would be
15 related mainly to my familiarity with the literature in
16 herbal medicine and for 24 years I was associated with
17 the Bureau of Drug Research and head of the Natural
18 Products Section in Health Canada. As such, I was
19 involved in developing methodology for analysis of
20 commercial herbal products and for providing guidelines
21 for the regulation of these products.

22 As you probably know, the system for regulation

1 in Canada is somewhat different from what is in the
2 United States. However, it would seem to me obvious that
3 the potential for herbal medicines contribution to health
4 care would seem to be fundamentally related to the
5 ability of the consumer to have access to safe and
6 efficacious products.

7 As it is now, judging the difference between
8 different commercial products is very hazardous and
9 limited mainly to the familiarity of the consumer with
10 the manufacturer.

11 It seems to me also that the prime imperative
12 for the health care system, and indeed for the regulatory
13 agencies, to ensure that the consumer can have access to
14 safe and efficacious products.

15 The large interest of physicians, health care
16 professionals in herbal medicines recently has been
17 concerned primarily with the ability to be assured of a
18 consistent therapeutic medicinal effect from these
19 products, and the plain fact is that knowledge of the
20 nature of active principles and the mechanisms of action
21 is severely limited.

22 Attempts have been mainly concentrated on

1 trying to characterize the substances chemically, but
2 there has been such a glaring lack of success in
3 identifying these active principles that I think the
4 recent trend to develop into biological assays would seem
5 to me to be the most promising combination, combination
6 of chemical and biological assays to establish some basis
7 for real standardization of these materials.

8 As it is now, there is very few examples where
9 one can be confident about standardization for consistent
10 effect.

11 I believe that the best contribution or
12 recommendation I can make is that a system, such as that
13 proposed by the World Health Organization for guidelines
14 for the assessment of herbal medicines, be instituted to
15 ensure proper identity and quality of both raw materials
16 and finished products.

17 Most of the adverse reactions, for example,
18 that have been recorded have been due to substitution,
19 adulteration largely due to misidentification or
20 linguistic confusion, and it seems to me that it is not
21 wise to leave the establishment of the identity and
22 quality of these materials to manufacturers, as the FDA

1 has recently suggested regarding the Aristalochia
2 problem.

3 There is such a very broad range of scientific
4 competence and technological capacity in this broad
5 spectrum of manufacturers, that it seems to me that sort
6 of reliance on manufacturers to ensure the identity and
7 quality of these materials is wrong-headed.

8 Also, I think that the effort that has been
9 made by the United States Pharmacopeia to establish sound
10 monographs, and there are a number of agencies that have
11 been involved in this, but I think that the approach of
12 the United States Pharmacopeia is commendable, and I
13 think that once they can get the proper group of people
14 together to establish reliable, accessible assays and
15 characterization of these materials, that we will advance
16 the process considerably.

17 DR. GORDON: Thank you very much.

18 Christopher Hobbs.

19 MR. HOBBS: Good morning and thank you very
20 much for inviting me today. I have certainly heard a lot
21 of good things from other presenters and certainly agree
22 with a lot of it. I am an herbalist and a licensed

1 acupuncturist in California and Oregon.

2 I have got a foot kind of in both worlds
3 because my mother and grandmother were herbalists, and my
4 dad was a scientist, so recently, for the last almost two
5 years, we have received funding from a large
6 pharmaceutical company, and we have been sifting through
7 the literature on a hundred herbs in great detail.

8 So, I am pretty familiar with what literature
9 is out there and what science is being done. Of course,
10 the quality varies quite a bit, as you know. But, for
11 instance, right now I am working on garlic. In our
12 database we have about 2- to 3,000 abstracts to sift
13 through.

14 Now, looking at all those abstracts, a lot of
15 them are animal studies, a lot of them are in vitro
16 studies, how many human studies have actually been done
17 of good quality on herbs, how many herbs out there could
18 you say that there really is good science, a medical
19 researcher would be satisfied with the amount of
20 evidence?

21 I would have to say that there are very few
22 herbs probably that have met that kind of international

1 scientific standard. Maybe hypericum or St. John's Wort,
2 ginkgo has a lot of evidence, and a few others, but when
3 you really look at the vast majority of herbs, for
4 instance, in the Chinese Pharmacopeia, there might be
5 5,000 herbs in the Chinese Pharmacopeia.

6 How many of those herbs have actually been
7 looked at scientifically with good science? I would say
8 very few especially with human studies.

9 I have submitted written comments, and I am in
10 the process of looking at more studies on efficacy of
11 herbs as far as cost effectiveness in our health care
12 system, and I would be happy to put together another
13 summary after I go home. I didn't really have much
14 chance. I was only called at the last minute, so I
15 haven't had a chance to write up the studies, but there
16 are an increasing amount of studies out there.

17 Actually, on herbs, generally, when you look at
18 the vast amount of research, it really is mind-boggling.
19 I had no idea until I started really looking out there.
20 We researched 26 international electronic databases and
21 accessed a lot of foreign material, and there really is a
22 lot out there to sift through.

1 Now, I have a few other comments just about
2 herbalism in general. My feeling and my recommendation
3 is that well-trained herbalists really should be involved
4 in studying the safety and efficacy of herbs on a
5 scientific basis because I would say that it is possible
6 that many scientists have the view that herbs do not work
7 until it is proven that they do work, whereas, an
8 herbalist might have the feeling that they work, my
9 feeling is that they work until it is proven that they
10 don't work.

11 So, I think that the questions that we ask in
12 designing studies are very important. Obviously, as
13 Dennis was saying, the quality of herbal products is so
14 important as when you really start looking at the cost
15 effectiveness of herbal medicine, we have to take into
16 account the quality of the herbs that are being used.

17 Now, a trained herbalist would know when to
18 harvest the herb, what season, what part of the herb.
19 This is a long history, a long tradition, and this type
20 of traditional knowledge has been passed down from
21 generation to generation, and can be quite detailed and
22 quite complex, although it is again difficult to study

1 scientifically.

2 Another thing is that I certainly agree that
3 herbs, as far as cost effectiveness and integration, work
4 a lot better when used in a traditional system. For
5 instance, many people today are using ginkgo for better
6 memory, so they go into the drugstore and they buy a
7 bottle of ginkgo for better memory, and this isn't always
8 going to be that effective, whereas, if you go to a
9 licensed acupuncturist or a herbalist that has
10 traditional knowledge and traditional training, this is
11 all integrated into a system whereby a person -- again, I
12 spend at least a half an hour, maybe an hour with
13 patients, and I consider myself their health coach. I
14 really encourage people to believe in their own innate
15 healing powers.

16 Herbal medicine really is a gentle medicine in
17 the sense that after all the years I have practiced, I
18 have seen really very few side effects. Yes, there are
19 side effects, and I would never say that just because it
20 is natural, it has no side effects, that is not true, but
21 generally speaking, herbs are far safer than drugs.

22 Thank you.

1 DR. GORDON: Thank you. We understand we put
2 you under time constraints, and we would very much
3 appreciate you sharing those studies with us. It would
4 be very helpful to us as we move ahead.

5 MR. HOBBS: Thank you.

6 DR. GORDON: Alan Gaby.

7 **Dietary Supplements**

8 DR. GABY: Thank you for inviting me. I am a
9 medical doctor, and my hobby over the past 25 years has
10 been collecting and looking at studies in the field of
11 nutritional and herbal medicine.

12 I have been amazed at how many studies there
13 are that are not known about in conventional medicine.
14 Some of them are double-blind, placebo-controlled trials,
15 some of them are case reports, some of them are
16 uncontrolled trials.

17 What we are dealing with here is substances
18 which are commodities, so therefore they are usually
19 quite inexpensive, and with a few situations where this
20 is not true, they are generally quite safe.

21 Having been in practice for 17 years, I have
22 not had a single patient have to go to the hospital

1 because of an adverse drug reaction, and most of the
2 people come in specifically because they are looking for
3 other ways of treating their conditions.

4 There is a legitimate concern in conventional
5 medicine that people will forego proven therapies and use
6 these instead, however, when people are guided
7 appropriately, and when they use their own common sense,
8 this doesn't occur.

9 There are only some situations, there are just
10 a few situations in conventional medicine where doing
11 nothing is dangerous. For example, if somebody comes in
12 and their joints hurt, and they are taking an anti-
13 inflammatory drug which is giving them an ulcer, and you
14 put them on niacinamide or glucosamine instead, and their
15 joints don't hurt anymore, there is no danger of
16 foregoing conventional therapy.

17 If somebody has migraine headaches and you put
18 them on magnesium and vitamin B6, and they don't have any
19 migraines anymore, there is no danger in them going off
20 of their beta blocker.

21 There are other situations where there would be
22 danger, for example, in congestive heart failure, but

1 even in that condition, if somebody is appropriately
2 monitored, and you can demonstrate that their ejection
3 fraction has gone up and their New York Heart Association
4 Classification has improved, then, one can cautiously
5 wean an individual off of their medication.

6 So, nutritional therapy has a large body of
7 evidence behind it, and it fits very much the allopathic
8 model. It is just that we are using different
9 substances. Interestingly, there appears to be more
10 resistance against nutritional supplementation among
11 academia than there is among some other CAM approaches.

12 As a matter of fact, there was a study
13 published in the Archives of Internal Medicine by a
14 conventional Ph.D. who provided evidence that there is a
15 bias against micronutrient therapy among academia.

16 In support of his argument, he showed that
17 textbooks almost universally neglect mention of vitamin E
18 for the treatment of intermittent claudication even
19 though there is evidence that it works as well as the
20 drug that is conventionally used.

21 In addition, there is uncritical acceptance of
22 adverse reactions, case reports where somebody is on six

1 hepatotoxic drugs and they happen to take a vitamin, and
2 they develop liver toxicity and they blame it on the
3 vitamin.

4 So, if we are going to move forward, we need to
5 utilize the research that has already been done. This is
6 one area of CAM where we actually could develop an
7 effective and cost effective approach right now based on
8 what has already been done.

9 I have given 10 examples in the handout. I
10 just picked those because they seem to be reasonable
11 examples. For example, \$1,000 a month for growth hormone
12 for a short child, 75 cents a month for zinc, which
13 according to one study works approximately two-thirds as
14 well as growth hormone. \$3.50 a month to prevent kidney
15 stones using magnesium and vitamin B6. \$200 or more per
16 month using the brand version of potassium citrate.

17 So, there are many situations where one can
18 clearly demonstrate cost effectiveness. On the other
19 hand, there is the possibility of over-utilization,
20 because there is an inherent block against using
21 prescription medications. People don't love to take
22 their prescription drugs, where often they love to take

1 their supplements.

2 So, we need to develop, in order to ensure cost
3 effectiveness, situations where it is appropriate to use
4 nutritional supplementation, and perhaps Medicare and
5 other insurance companies should pay for them as an
6 alternative or as an adjunct, and that there are other
7 situations where it may not be appropriate, such as the
8 walking well who want to take their supplements as
9 opposed to the walking wounded who are already spending
10 thousands or tens of thousands of dollars.

11 As a final 23 seconds worth, I want to mention
12 something slightly off of my scope here, and that is the
13 identification of food allergy in the treatment of
14 conditions. I saw people that have spent thousands of
15 dollars on care that didn't work and in one visit they
16 were cured of their chronic problem because they had a
17 food allergy which was not identified.

18 So, we need to teach this in medical school,
19 and the cost of care will come down by billions of
20 dollars.

21 DR. GORDON: Thank you. Thank you for your
22 superb timing, Alan, and also for these examples, very

1 useful.

2 Patsy Brannon.

3 **Nutrition**

4 DR. BRANNON: I, too, want to thank you for the
5 invitation to speak to you about nutrition as a
6 complementary and alternative medicine. I am a
7 registered dietitian and a research nutritional
8 biochemist.

9 I want to start by discussing nutrition as a
10 very broad continuum in health care. It ranges from
11 self-selected diet or dietary supplement choices by
12 consumers with no consultation with any health care
13 provider of any sort, to medical nutrition therapy in
14 conventional health care ambulatory and acute care
15 settings.

16 The recent Institute of Medicine report on the
17 role of nutrition and malnutrition in maintaining health
18 in the nation's elderly defines two tiers of nutritional
19 services, and I think this is an important distinction to
20 consider as you consider complementary and alternative
21 medicine.

22 The first is basic or general nutrition

1 education or advice that can be provided by a variety of
2 health care professionals including physicians,
3 dietitians, nurses, chiropractors, dentists, physical
4 therapists, clinical social workers, physician
5 assistants, pharmacists, psychologists, and others.

6 The second tier, however, is nutrition therapy
7 or medical nutrition therapy, which involves nutritional
8 assessment, evaluation of nutritional needs,
9 intervention, counseling, enteral, parenteral nutrition,
10 and other modalities, as well as follow-up care. This is
11 generally provided primarily by registered dietitians in
12 a health care team of physicians, nurses, pharmacists,
13 physical therapists, and psychologists.

14 Beyond these two tiers, however, exists the
15 vast majority of information going to consumers about
16 nutrition, and that is through the mass media. There are
17 recent survey data that suggest that this is the primary
18 source of information about nutrition for consumers and
19 that fewer than 5 to 9 percent of consumers seek
20 nutritional advice from a health care professional, such
21 as a dietitian or a physician.

22 I am going to focus my remarks today on

1 nutrition therapy in part because I knew Alan was going
2 to speak about dietary supplements and, in part, because
3 this is the area where we have the best research base
4 evaluation of clinical effectiveness and cost
5 effectiveness.

6 This is not to say that we don't need to
7 evaluate basic nutrition education, Tier 1 services, and
8 that need remains high, and it is also not to say that we
9 don't need to determine clinical effectiveness of other
10 dietary interventions because we do.

11 Nutrition therapy is strongly supported by
12 observational studies, consensus documents, systematic
13 review, and extensive clinical trials of a wide variety
14 of size for the following conditions: dyslipidemia,
15 hypertension, diabetes, by reference obesity, and
16 osteoporosis.

17 Evidence with less robust clinical trial data
18 also exist for heart disease, predialysis kidney failure,
19 and under-nutrition. Less robust data, relying primarily
20 on observational data and epidemiological data, with less
21 robust clinical intervention data exists for Alzheimer's,
22 osteoarthritis, cancer, and other conditions.

1 The cost effectiveness of nutritional therapy
2 has been examined in several contexts. There are two
3 Lewen reports, one commissioned by the American Dietetics
4 Association on Medicare benefits, and study was done in
5 1997, and I will leave a copy courtesy of the American
6 Dietetics Association for you.

7 This estimates that a net seven-year cost to
8 cover all Medicare beneficiaries for the nutritional
9 therapy for the diseases for which there is strong data
10 would be \$370 million, an estimate savings including
11 decreased hospitalizations and patient benefits at \$1.2
12 billion for the same period. Savings is greater than the
13 cost by the third year of this seven-year analysis.

14 Another study done by Lewen for the Department
15 of Defense on tricare system estimates a net savings of
16 \$3.1 million per year by providing nutrition therapy.

17 A recent medical cost nutrition containment
18 study that was done by the Oxford Health Plan on an
19 expanded pilot program for the Elderly at Nutrition Risk
20 in New Jersey and New York, which included 160,000
21 elderly patients, estimated a \$10.00 savings per dollar
22 invested in the program.

1 In a study by Gallagher and co-workers reviewed
2 research on malnutrition in hospitalized patients and
3 estimated a \$4.20 benefit per dollar invested.

4 The clinical effectiveness I won't have time to
5 summarize, but it is extensive. The cost effectiveness
6 data are here for these studies, and the delivery was
7 primarily by dietitians with adults in acute and
8 ambulatory care settings.

9 We have one study that suggests there is a high
10 degree of patient satisfaction with nutrition therapy,
11 but more studies are clearly needed. We have a number of
12 barriers to nutrition therapy, and I am going to echo the
13 themes that have already been sounded.

14 The lack of recognition of nutritional therapy
15 by dietitians and other nutritional professionals by
16 Medicare and Medicaid in private practice health plans is
17 clearly a problem.

18 Recommendations. We have legislation currently
19 in Congress, H.R. 1187 and S. 660 to provide outpatient
20 medical care coverage for medical nutrition therapy for
21 diabetes and kidney disease, and we need this
22 legislation, as well as to consider expanded Medicare and

1 Medicaid coverage as recommended by the Institute of
2 Medicine report for the other chronic diseases for which
3 nutritional therapy has been documented effective.

4 We need to reevaluate reimbursement systems,
5 and we need to think about the research that is needed on
6 efficacy, safety, and cost effectiveness, particularly on
7 plant, food components, and phytonutrients for which many
8 questions exist.

9 Thank you.

10 DR. GORDON: Thank you very much. We will look
11 forward to the study.

12 Our final speaker on this panel we are actually
13 giving 10 minutes to because he is talking about
14 integration, so you can either take them all or take less
15 as you choose. Harley Goldberg, who will talk about
16 integrating a number of CAM approaches.

17 Integrated Overview

18 DR. GOLDBERG: Thank you very much. I am the
19 medical director for Complementary and Alternative
20 Medicine for Kaiser Permanente in Northern California,
21 and I appreciate your inviting me to speak, and take a
22 slightly different view.

1 We have heard some very compelling statements
2 by a large number of presenters here, and I think you
3 appreciate the difficulty of wrapping and lumping all of
4 these issues together and calling it CAM when they
5 actually need to be looked at independently in a case-by-
6 case basis in order to evaluate effectiveness.

7 For the very reasons that your commission has
8 been executed by executive order from the President, for
9 the same reasons our executive director appointed a
10 director of Complementary and Alternative Medicine to
11 provide information on complementary and alternative
12 practices to our physicians, to our members, to our
13 health care providers of all types to coordinate a
14 research program, to evaluate what education and training
15 would be appropriate for providers that we were going to
16 integrate into our program, and to identify what would be
17 the appropriate access and delivery systems, much more
18 than I could possibly cover in 10 minute, much less five.

19 So, we have taken a few steps to move forward
20 and because of that, I was asked to discuss how we have
21 gone about addressing these issues. By no means have we
22 solved them all, but I will explain to you the steps that

1 we have taken in order to try to grapple with the issues.

2 First, our history. I explained briefly in
3 your handout what Kaiser Permanente is, so that you can
4 appreciate the size of the organization and the
5 complexity of trying to answer some of these questions,
6 but initially, we also did a survey much as Dr. Gordon
7 reviewed the surveys at the outset of this meeting. It
8 was published in the Western Journal of Medicine in
9 September of 1998.

10 I will be glad to make that available to you if
11 you need it, but it basically gave the same kinds of
12 illustrations of data that you reviewed and showed that
13 there was a very strong interest amongst our members and
14 our patients, as well as amongst our physicians and
15 clinicians in complementary and alternative medicine, and
16 it outlines by breaking down, modality by modality, the
17 percentage of interest.

18 Suffice it to say that 50 to 75 percent of our
19 members were using, and are interested in using, various
20 CAM modalities. How you define that always changes the
21 numbers.

22 In addition, however, what was really

1 surprising to us was the same percentage was true for our
2 physicians and health care professionals. That actually
3 is what generated the appointment of my office, and the
4 way we have recognized drivers for this issue basically
5 is that there are two drivers. Members have a belief in,
6 and demand for, CAM services.

7 Physicians have a request for evidence,
8 physicians and all health care providers have a request
9 for evidence and safety and effectiveness in order to
10 know how to meet those demands. Therein is the tension,
11 and to address that we basically chose which CAM areas to
12 evaluate based on the prioritization of member interest
13 and how to evaluate them was based on the physician
14 requests for summaries of the evidence on safety and
15 effectiveness, not unlike the discussions we have heard
16 earlier today.

17 I guess I should say overall our approach to
18 complementary and alternative medicine as an integrated
19 health care delivery system is no different than that
20 approach that we take to our overall program.

21 Our strategy is to incorporate services that
22 are safe and effective treatments, providing the best

1 access and most efficient service, through integrating
2 that in our health care delivery system. That means we
3 have major medical centers and satellite facilities with
4 providers of all types integrated throughout the State of
5 California.

6 So, we approach CAM in precisely the same way.
7 In order to do that, our advisory panel was appointed
8 with representatives from education, research, executive
9 offices, and clinicians involved in actually practicing
10 modalities that were the primary areas of interest.

11 This advisory panel directed the process and
12 made policy recommendations as we move along. The areas
13 of interest that were revealed in the survey were grouped
14 into general categories with all the difficulties that
15 that might incur.

16 Those were manual therapies and movement
17 programs, traditional systems of medicine. Subsets of
18 that would be acupuncture. Mind-body approaches to
19 medical care of which there are many, and nutritional
20 supplements, herbs, and dietary approaches, as well.

21 Given the magnitude of these areas, we
22 prioritized our work by differentiating, perhaps

1 arbitrarily, treatments that were for treatment of
2 disease, and then methods for health promotion.

3 Those treatments that were used for treatment
4 of disease were evaluated for safety and effectiveness,
5 and, when warranted, would be considered for integration
6 by physician referral.

7 Because of the nature of the fact that there is
8 a disease state involved, we felt it incumbent upon us to
9 be fully responsible for appropriately working up
10 diagnosing, et cetera, and rolling treatment into that.

11 For those methods that were identified
12 primarily as health promotion, they would be evaluated
13 for integration into an integrated health education
14 program that we have, that is integrated into all of our
15 facilities, and that would be by self-referral as
16 distinctly different from treatments for diseases.

17 The advisory panel then commissioned standing
18 committees on education and research. The Education
19 Committee has basically two charges, one to provide the
20 summary of information to our physicians and health care
21 providers, and the other to produce information along
22 with our Health Education Department, in another

1 language, if you will, for membership, as we term the
2 public or patients, all the same people.

3 The advisory panel commissioned
4 multidisciplinary work groups for each of those areas
5 that were lumped, if you will, to evaluate the evidence
6 for safety and effectiveness for each of these areas.

7 Essentially, this amounted to performing
8 systematic reviews, and as several people have talked
9 about, how much literature there is out there, that is a
10 daunting task.

11 Having been at it for a while, I can assure you
12 that it is not as easy as it is to say, and we can talk
13 about that a little bit more at the end, if you like, but
14 systematic reviews basically drive the information.

15 All of this discussion is trying to put
16 ourselves on a foundation of what works and what is safe
17 or not safe, or what doesn't work or why, and that all
18 skirts an issue that we need to talk about at the end
19 about belief, which may be that interface between the
20 public's demand and the clinician's need for evidence-
21 based, placebo-controlled, randomized trials.

22 Having said that, the systematic reviews drive

1 the information that the Education Committee puts out for
2 members and for clinicians. It also informs the research
3 agenda that is driven to answer the questions unanswered,
4 and therefore becomes the foundation of the work.

5 It is also used, this information is also used
6 in consideration of what services to deliver. In
7 general, to be considered as a treatment for a condition,
8 that is, a treatment for disease, that is, we require
9 that there is reasonable evidence of safety and
10 effectiveness.

11 In addition, we ask that a quality assurance
12 system be available before we take the next step of
13 considering integrating something into a treatment
14 program for treatment of disease.

15 Who provides the service and where is actually
16 determined by very practical issues in the context of our
17 overall integrated health care system, and we can talk
18 about numbers of examples if we have dietitians involved
19 and dietary care.

20 If we have various practitioners of manual
21 therapies involved, where do those people actually live
22 are they in the Ortho Department, in Physical Therapy

1 Department, are they in Primary Care, et cetera.

2 There are answers actually to all of these
3 issues, but, in fact, what happens when you look at it
4 carefully is that there are many answers. It depends on
5 the size of the facility, if it is a small facility in a
6 rural area versus a large medical center in a major area
7 versus whether or not there is a specialty care process
8 involved or primary care process involved.

9 Suffice it to say, it is not one answer, and it
10 is not a simple answer, and it is not a restrictive
11 answer. It is a "both and" answer, in other words, we
12 can have, as we do, physical therapists in our primary
13 care modules, as well as in our Orthopedics Department,
14 as well as in a free-standing department and how we
15 integrate who sees them, when and how is dependent on how
16 the patient presents with their clinical condition and
17 where.

18 So, we are considering systems further to
19 deliver services when there is evidence of safety but
20 effectiveness is unknown, which, as has been stated
21 before by panelists, is largely the case.

22 When that is the case, actually, what we are

1 looking at is a self-referral system that is at patient's
2 cost, and something that hasn't been talked about much,
3 but should be, because it drives all of this really is
4 who pays. You have to identify that, and basically, we
5 are looking at various models to try to answer that.

6 It is not easy. There are many ethical issues
7 involved. It is very difficult to sometimes determine
8 when a therapy is a treatment of disease versus for
9 health promotion.

10 We want to encourage health promotion, at the
11 same time, who pays is an issue when you have a single
12 dollar, if you will, pot to pay for all services, and I
13 sit down in the Chiefs of Medicine peer group meeting to
14 discuss implementation of all of medical care for that
15 department, and they look at me knowing what I am doing
16 and say you are the guy who wants to take some of the
17 money, this is essentially taking another primary care
18 provider out of the office or someone off call or someone
19 out of the ER in order to provide these other services.

20 The only way to answer those questions is with
21 good evaluations that show that we have equally or more
22 effective care that helps them and helps our member and

1 our patient most importantly, provide them the best
2 health care available.

3 So, my policy recommendations, if I may
4 quickly, is that we need to fund an organized systematic
5 reviews in a coordinated fashion on specific CAM methods
6 and by clinical conditions. This will be the basis of
7 the evidence-based approach in forming the educational
8 materials, and the research agenda.

9 We need to increase research on clinical
10 implementation of specific CAM treatments for specific
11 conditions involving CAM practitioners and experienced
12 researchers, and we need to compare that to standard care
13 that is largely nonexistent right now.

14 Creating and supporting public and clinical
15 information systems out of that, and then accelerating
16 the research focused on belief and mind-body medicine
17 which lies at the interface of these two driving forces.

18 I would like to acknowledge that one of my
19 colleagues, David Sobel, who is the Director of Health
20 Education, was asked to come and present mind-body
21 medicine, but was unable to attend, so his materials are
22 in your packets. Very clear cost effective analyses are

1 done on mind-body approaches, and I think there is little
2 question about the effectiveness and safety of those
3 approaches.

4 DR. GORDON: Thank you very much, and we will
5 be asking David and some of this colleagues perhaps to
6 come back at a future session.

7 Questions from the commissioners.

8 Veronica.

9 **Panel Discussion**

10 DR. GUTIERREZ: I would like to ask Dr.
11 Goldberg two questions actually. The first is which
12 services are you providing based on guidelines versus
13 clinical necessity, and secondly, what services require
14 gatekeepers at the present and who fills the role of the
15 gatekeeper?

16 DR. GOLDBERG: Guidelines versus clinical
17 necessity? I am sorry, I don't understand. We developed
18 these recommendations. You could call those guidelines.
19 Those are driven initially to be looked at by clinical
20 necessity, but to answer your question about which
21 services, specifically, we provide acupuncture services
22 in the context of chronic pain programs.

1 There is actually multiple answers here because
2 there are answers around what we do as an integrated base
3 coverage in our entire system versus other methods of
4 delivering systems as supplemental riders by self-
5 referral and/or access through affinity programs, if you
6 appreciate what I am talking about.

7 Those are just health care delivery systems
8 issues, but I will presume your question is about base
9 and then I will say that right now we are integrating
10 acupuncture as one component of our chronic pain delivery
11 systems, and that is a multidisciplinary program that is
12 one aspect of it.

13 In addition, manual therapies are provided
14 through our Physical Therapy Departments. Health
15 education programs have a whole array of choices of mind-
16 body approaches. That will be where I would stop for
17 now.

18 Is that answering the question you are asking?

19 DR. GUTIERREZ: Yes.

20 DR. GOLDBERG: I think there was a second half,
21 but I am not sure I got it.

22 DR. GUTIERREZ: I was asking who plays the role

1 of gatekeeper?

2 DR. GOLDBERG: Oh, right. That is the
3 differentiation between if a service requires physician
4 referral and if a service is available on self or patient
5 referral. Basically, if it is a specific treatment for a
6 clinical condition, it requires a physician referral, and
7 the primary care provider, if you will, is the gatekeeper
8 although referrals can come from any specialist or any
9 provider in the system.

10 DR. FINS: This is a related question for Dr.
11 Goldberg. What kind of consensus was generated, tell us
12 a little bit about the process, were consumers
13 participating in this process, was there disagreement,
14 where were the fault lines, where do people sort of
15 disagree, and how did you read those bright line
16 distinctions which look good on paper, but were probably
17 difficult to achieve?

18 DR. GOLDBERG: Right. I appreciate your
19 sensitivity to that. Basically, we selected, as I said,
20 the areas that we would evaluate based on the surveys,
21 which were done of tens of thousands of members, and the
22 summaries of those surveys, which is actually in that

1 article I referenced in the Western Journal of Medicine,
2 September of 1998, Nancy Gordon and David Sobel, lead
3 authors, basically, we used that as our guide to start
4 with, and then we used multidisciplinary clinicians, so
5 depending on the thing we were evaluating, clinicians
6 involved in that service, as well as some clinicians
7 experienced in epidemiologic systematic review process to
8 evaluate the data.

9 So, we didn't actually have members involved in
10 reviewing the evidence because we didn't feel that was
11 where they could be most helpful, but they were involved
12 in selecting what we chose to review first.

13 So, actually, my request of this panel is that
14 the Commission provides funding and support for
15 systematic reviews that would be done to help Christopher
16 and to pay Christopher to review herbs for us, and so
17 then I don't have to repeat what he is doing.

18 Obviously, he is doing a much more thorough job
19 perhaps than we did on the beginning of our herbs. It is
20 scattered throughout and it is the same evidence data,
21 and if we had respected people doing that work for us as
22 a whole, the whole country and world would benefit.

1 DR. GORDON: Let me say who I have. I have
2 George Bernier, George DeVries, Bill, Tieraona, Ming, and
3 Wayne. Anyone else? Okay. David afterwards.

4 Go ahead, George, and then George.

5 DR. BERNIER: I would like to ask you about the
6 educational process. Since that is one of the areas that
7 we have been asked to really comment on, you have had the
8 opportunity to develop educational processes for people
9 at various levels.

10 What would your idealized system be? How could
11 you best educate the population --

12 DR. GOLDBERG: When I asked that question to
13 our director of Physician Education, her answer was eight
14 times, eight different ways repetitively meaning to say
15 that what we do, in fact, is provide information in
16 written format on paper electronically, in summarized
17 versions, in full guideline versions including the
18 bibliography of all the work we did, the evidence tables
19 that we created, the summaries of that clinical
20 information.

21 In addition, by video conference presentations
22 which we do on a quarterly basis for our system as a

1 whole, et cetera. Members also, and public, in addition,
2 want education, and basically the answer is that it is an
3 entire effort that must be conducted periodically and
4 repetitively on each of the areas of interest.

5 Is that answering your question?

6 DR. BERNIER: Yes. Thank you.

7 DR. GORDON: George.

8 MR. DeVRIES: This question is directed to Dr.
9 Awang, Dr. Gaby, and Christopher Hobbs.

10 Do you have recommendations on improvements
11 that could be made to labeling regulations for herbal and
12 dietary supplements based on some of the concerns that
13 were expressed?

14 MR. HOBBS: One recommendation I have is to
15 talk about a traditional medicines category because again
16 there are so many herbs out there that are being sold and
17 being used, for instance, 5,000 herbs in the Chinese
18 Materia Medica, probably in this country, commonly used
19 500 herbs or maybe at least 100 or 150 herbs in the
20 common herbal practice, and we can't have the level of
21 evidence that we would like in the next few years.

22 This is going to take years and years. It is

1 difficult to study herbs because they are not
2 monosubstances, they are so complex. So, a traditional
3 medicine category basically would look at the historical
4 and traditional, the best evidence in historical and
5 traditional medicine, which is vast, and it goes back
6 several thousand years.

7 Hippocrates already talked about using Vitex
8 Agnus-Castus for hormonal imbalances, Dioscorides, which
9 is a Greek physician in the first century A.D., talked
10 about St. John's Wort for mania.

11 So, this has been around for a long time, but
12 if we have a traditional medicines category where the
13 best evidence of traditional use and efficacy is taken
14 and reviewed, and then manufacturers are able to put
15 these types of recommendations on their label, to better
16 educate consumers how to use these medicines or herbs,
17 because they are out there on every level.

18 They are in the drugstores, they are sold
19 everywhere, and multilevel marketing, and so forth, and
20 frankly, a lot of the advertising and a lot of the
21 information that is going out is not very good, it is not
22 high quality, and on the web you can read anything. What

1 I have seen out there is just ridiculous.

2 So, obviously, we can't study scientifically
3 and prove all of these herbs that are being used right
4 now, today, in a very short time. We have to have some
5 system, so that manufacturers and some guidelines, and
6 American Herbal Products Association is working on this,
7 American Herbalist Guild, some other organizations are
8 working on recommendations to the FDA for a traditional
9 medicines category.

10 DR. GABY: My answer is similar. In relation
11 to nutritional supplements, there is a lot that is
12 already known as far as adverse effects, other
13 interactions, for example, with drugs or nutrients, and
14 there is also a lot that is known on efficacy.
15 Apparently, there is a law about what you are allowed to
16 say for efficacy, but you can always say what the
17 strength of the evidence is, for example, an uncontrolled
18 trial showed that something works, or Dr. Jonas' double-
19 blind study showed that niacinamide is effective for
20 osteoarthritis.

21 If you are taking more than a certain number of
22 milligrams, see your doctor. If you are taking so-and-so

1 drug, do not take this without seeing your doctor. This
2 would greatly enhance both the effectiveness and the
3 safety, and it would probably greatly reduce the number
4 of visits to doctors without causing harm to people.

5 DR. AWANG: First of all, I would like to say
6 that there is a lot of information that can be put on a
7 label, and a lot of information has been put on a label.
8 Much of the information is unreliable.

9 I think at this point of the state of
10 regulation of these materials, which I think just about
11 everybody agrees they are pharmacologic agents, not
12 nutritional supplements, that the most useful information
13 you can put is warnings against possible adverse effects
14 or toxicity, and recommendations as to use, but that is a
15 very difficult area because if you are not going to allow
16 claims about treatment of disease, conditions, and so
17 forth, then, you are severely limiting what you can put
18 on the label.

19 In fact, the pharmacologists, in an article
20 some time ago said -- I will read it here verbatim --
21 "Rather than claims to treat disease, one sees vague
22 suggestive comments on herbal product labels and

1 advertising material."

2 For example, Saw Palmetto is supposed to
3 promote prostate health rather than treat symptoms of
4 benign prostatic hyperplasia, which I think everybody
5 knows is what they are buying it for.

6 So, at this point, I mean you see so many
7 labels of Saw Palmetto saying 85 to 95 percent fatty
8 acids. Now, I have serious doubt that you can rely on
9 that content in the vast variety of products that claim
10 that.

11 What has happened is that when the original
12 clinical research was done, and the material properly
13 characterized, the estimation was that the fatty acids
14 ranged between 85 and 95, so everybody else does that, as
15 they do for 24 percent of flavonoid glycosides and 6
16 percent terpene lactones for just about every ginkgo
17 product you see.

18 So, unless this area is better regulated, I
19 think the usefulness of the label is severely limited.

20 MR. HOBBS: May I make just a quick comment?

21 DR. GORDON: Yes. One thing I want to say to
22 everybody is for this panel, we have 15 minutes more and

1 we have to end.

2 MR. HOBBS: Just that the label is more than
3 what is on the bottle. Remember that many manufacturers
4 use magazine articles, advertising on the web, and so
5 forth, to advertise, so really we have to consider the
6 wider conception of the label is a lot more than just
7 what is on the bottle.

8 DR. GORDON: Bill.

9 DR. FAIR: My question is to Dr. Brannon.
10 First of all, thank you for this nice handout. As I look
11 at the mosaic of nutrition, I see there is the proper
12 eating portion, which I guess is nutritional therapy, and
13 then I think there is a role of supplements and some
14 diseases, vitamin E in heart disease, or Saw Palmetto,
15 but I keep getting more and more questions from people
16 recently about some of these approaches, what I guess you
17 would call taking function foods and desiccating them or
18 lyophilizing them and putting them into a capsule or a
19 drink, I guess 2-Plus or something like that is one, and
20 it is often sold through a multilevel marketing system.

21 My specific question is, is this a valid
22 approach, is this something that should be considered as

1 a way of increasing access to good nutritional habits if
2 people say they don't have the money or they don't have
3 the time to eat the way you would tell them to eat?

4 DR. BRANNON: I think that we are going to see
5 more and more functional foods, so the issue of whether
6 it is appropriate or not is probably a lot less important
7 than how we are going to handle it.

8 You are going to see more, and I think it is
9 being driven by consumer demand, benecol-containing
10 margarine is a good example of that. However, what we
11 are missing -- and I think it is a thing that we are
12 missing in all of nutrition -- is how does it fit with
13 what the diet as a whole is.

14 So, some of these foods, if a consumer thinks
15 that they are going to use benecol-containing margarine
16 in a high fat diet that has a lot of other saturated fat
17 without any of the rest of the aspects that we know are
18 part of a healthy diet for an average American, that is a
19 misconception, and it is not one that, as I looked at the
20 literature available, the literature available addresses
21 very well.

22 So, when I said I thought there was limited

1 data on dietary supplements -- and I would put functional
2 foods as maybe an unusual category of a dietary
3 supplement -- in the context of the diet as a whole, it
4 is hard to know, looking at these studies, what the rest
5 of the diet looks like.

6 I think that is part of the efficacy problem
7 that we have in evaluating nutritional therapy.

8 DR. FAIR: If people are skipping adequately
9 eating, can they make up for it by taking pills or
10 drinks?

11 DR. BRANNON: Well, that gets to the fact that
12 for many of the issues we don't know what the bioactive
13 food components are really, and I would point to the
14 recommendation that still holds up, which is increasing
15 the consumption of fruits and vegetables decreases your
16 risk of cancer.

17 The hypothesis that was beta carotene mediated
18 doesn't appear to be true, and, in fact, we have some
19 evidence that beta carotene in high levels is not safe
20 and can actually increase the risk of cancer.

21 So, what it is, is that there are many things
22 in foods, and this is, I think, an important fundamental

1 principle as we move forward, that small amounts of many
2 different substances together can be more effective than
3 large amounts of any single substance, and we frankly
4 don't have data that evaluate that.

5 DR. FAIR: My question is still do you have to
6 eat the fruits and vegetables to get this effect or can
7 you get it in a capsule or a drink that is supposedly
8 made from the juice of all these fruits and vegetables
9 put together?

10 DR. BRANNON: I don't think we have enough data
11 to give you a yes or no answer on that.

12 DR. GORDON: Tieraona.

13 DR. LOW DOG: It is sort of on the tail end of
14 that. You know, listening to all of this and talking
15 about access and delivery, there is such a big spectrum,
16 isn't there, from just talking about food and how you
17 prepare your food and eating a healthy diet to taking
18 megavitamins or orthomolecular medicine, heavy
19 nutritional supplements, and there is also the same
20 argument with herbs, using whole herbs, which again comes
21 back to whole foods and recognizing that there is
22 probably lots of things in there that work together to

1 make it the whole more than just the sum of its parts,
2 and then there is standardized extracts, there is this
3 huge range, and part of what we are trying to figure out
4 is how to make recommendations, how do you make
5 recommendations that will enhance the access delivery in
6 health care of people here.

7 I guess I would like some ideas from you all
8 when there is such a broad spectrum, from whole herbs,
9 whole foods to minute dietary supplements, ancient wisdom
10 that has been around forever, and now new scientific
11 technology with very complex kinds of things.

12 How do we begin to address that, how do we
13 begin to make recommendations when it is so big and so
14 vast? Chris.

15 MR. HOBBS: My feeling is we will never
16 understand, we will never get to the bottom of the
17 complexity and the mystery of herbs and foods. Also, to
18 address your question, will juice powders give you the
19 same thing as a whole food, no, they will never give you
20 the same thing as a whole food. They can approximate it,
21 they can help supplement if a person is not eating any
22 fruits and vegetables, then, a juice powder is probably

1 better than nothing at all.

2 As far as herbs go, my feeling again is that go
3 back to the traditional herbalism, there is still, even
4 in this modern science of all the studies and all the
5 science, there is still a place for traditional medicine,
6 there is still a place for a traditional system of
7 medicine like traditional Chinese medicine, Ayurveda,
8 because it deals with whole substances, it deals with the
9 whole herb in a context that is very, very ancient, and
10 it also deals with people.

11 We are not considering so much that --
12 standardization just hasn't have to do with the herb and
13 identifying the chemical constituents and the
14 pharmacological action. It also is how does that herb or
15 food interact with the person or the patient.

16 This is what traditional medicine studies, so
17 each person is evaluated, each person is looked at in the
18 context of that system, and then the herb and the food is
19 applied.

20 So, I think, just to sum up, I think we have to
21 go back to traditional medicine and we have to promote
22 the study of traditional Chinese medicine, Ayurveda, some

1 of these systems that looks at the whole person and the
2 whole food and the whole herb in the context of an
3 ancient practice, and we can fragment these herbs and
4 study them to death, but we will never get to the bottom
5 of all the mysteries that are included in there, although
6 I think we should try.

7 DR. BRANNON: I would also like to comment in
8 the sense that I think that in the absence of knowing
9 about effectiveness, that it is important we know about
10 safety, and one of the guidelines for food, in
11 particular, in diet, is that people make food choices for
12 a lot of reasons, and as long as the food choices they
13 are making are safe or don't have an adverse effect,
14 then, how much should we worry about that particular food
15 choice.

16 I would argue that in this context, we should
17 probably worry about the food choices or supplement
18 choices for which there are adverse effects.

19 DR. AWANG: I would just like to make a brief
20 comment about the whole versus extract thing on the
21 traditional versus modern usage. I feel fairly confident
22 that you can't take enough ginkgo leaf to affect your

1 memory, but because the modern evidence for it is for
2 highly concentrated extract, a 50 to 1 extract of ginkgo
3 leaf, and that is what has been shown to be useful in
4 Alzheimer's and memory, and so forth, but I don't think
5 you are going to get it in corn chips or in a food drink.

6 Also, ginkgo itself has toxic materials in it,
7 and you have to remove the ginkgolic acids and the ginkgo
8 toxin, so one has to be very careful about that, as well.

9 DR. GABY: Just so we don't overlook what may
10 be most important in the discussion of standardized herbs
11 and concentrated nutrients and Juice-Plus, which probably
12 should be called Juice-Minus, we talk about functional
13 foods when our real policy, since the evidence is that
14 eating whole foods or avoiding dysfunctional foods
15 promotes health, we can create a policy which is somewhat
16 outside the scope of medical care, but within the purview
17 of the public health, to promote the use of whole foods
18 in our society, and as a public policy, it is very simple
19 to do that. That would be to tax junk food and to give a
20 subsidy to whole food.

21 [Applause.]

22 DR. GORDON: Harley.

1 DR. GOLDBERG: Just in response to Dr. Low
2 Dog's comment, we cannot do randomized clinical trials on
3 very specific questions and get quick answers, it is a
4 long process. However, to answer questions quickly, you
5 can use epidemiologic data and other types of studies on
6 populations which have been done, for example, the
7 Chinese data on the use of soy in menopausal symptoms, et
8 cetera, and get good, relatively quick answers to begin
9 the process, so the short answer has to come from other
10 types of studies than randomized clinical trials, and the
11 spectrum of types of trials that are used and how they
12 are weighted in terms of evidence and what that means is
13 standard and is available, and we ought to use it.

14 DR. GORDON: Ming. I think we are just going
15 to have time for Ming and for Wayne, and we are going to
16 have to end. We need time to digest our whole food
17 lunch.

18 DR. TIAN: My question is, I think that herbs
19 are very important, easy, and also very complicated, and
20 are we talking about the medicinal herbs or are we
21 talking herb, because in this country, FDA regulates herb
22 as a food supplement or a dietary supplement, so if it is

1 a medicinal herb, you should go to pharmacist or industry
2 to do that.

3 When we do the herb, I think it will be very
4 important to address the issue, what are the herbs
5 commonly used, and also very safe, if you experts can
6 list this, to submit a list or with any scientific
7 support.

8 Number two, if the herbs with any health claim,
9 as FDA requires, any label, you have to put that on it,
10 but you can't say that is a cure or prevention or treat
11 any disease, but again, what kind of a health claim would
12 be reasonable to put on the label to guide the American
13 public, and the medical profession, and to tell people
14 which one is useful and what is dosage, or you want to
15 use serving size, whatever you want to use, but that is
16 very important.

17 I think American public and also medical
18 professionals are a little bit confused, a lot of them
19 are confused. They don't know which herbs you should
20 take, so that is very important.

21 Number three, you know, WHO already has the
22 guideline for herbal medicine, they call "herbal

1 medicine," what we call "herbal remedies," whatever you
2 call, it is the same thing. Then, should we adopt that
3 guideline for the United States, otherwise, how do we
4 evaluate such a big issue? That is my question. Thank
5 you.

6 DR. GORDON: All in 30 seconds or less.

7 MR. HOBBS: Oh. Well, first of all, there
8 again we talked about traditional medicine and whole
9 herbs. That generally can be thought of as being maybe a
10 little safer than when you start purifying herbs, like
11 Dennis mentioned, ginkgo, 50 to 1 extract.

12 Once you start isolating compounds and
13 purifying them, then, you get into a whole different
14 ballgame. I think, in that case, then, if you are using
15 science and you are using fractionation to isolate
16 compounds, this is closer to drugs, is it not?

17 Then, I think you have to have more safety
18 data, you have to have more efficacy data, and because it
19 is a different context now. You are getting into modern
20 science, you are getting into more pharmacy, and so
21 forth. Then, it requires more science, more efficacy
22 studies, more safety data, and more very specific

1 labeling guidelines, whereas, with traditional medicine,
2 then, you are working with a practitioner who understands
3 the whole herbal medicines and applies it to a system of
4 practice.

5 So, it depends. I think there is a very real
6 division here between modern scientific herbal medicine,
7 fractionated herbal medicine, and traditional herbal
8 medicine, but I think both are necessary and both are
9 applicable, and both can be effective in our country.

10 DR. GORDON: Wayne.

11 DR. JONAS: Thank you. One short question also
12 to Mr. Hobbs. How do you know when you have a qualified
13 herbalist?

14 MR. HOBBS: At this point, there are about five
15 schools of herbal medicine in this country, also
16 naturopathic physicians, which there are three approved
17 schools, also study herbal medicine. Nowadays,
18 chiropractors have some herbal training.

19 But really anybody can call themselves a
20 herbalist. There are no guidelines. In fact, I believe
21 that herbal medicine is not a real career choice in this
22 country. There are no real guidelines for it. There is

1 no official terminology or definition for what an
2 herbalist is. So, we are trying to do that now.

3 The American Herbalist Guild is the only
4 national organization in this country, and we currently
5 are working on registration. So, we are developing
6 educational standards, we are talking about registration,
7 that you take a test and you put your name on a
8 registration roll, so at least a person knows that if you
9 are a registered herbalist in the American Herbalist
10 Guild, you have a certain modicum of training.

11 But other than that, it is going to take time,
12 because there are so many different traditions, are there
13 not? There is traditional Chinese medicine, Ayurveda,
14 Western herbalism, and so forth.

15 So, this is going to take time to integrate it,
16 but it is a very exciting time in herbal medicine today
17 because all of these influences are coming to this
18 country, Ayurveda, Chinese medicine, so we are working
19 all this out right now as we speak, but I certainly agree
20 with you it is not easy.

21 DR. GORDON: Thank you very much. I apologize
22 to Charlotte and Tom.

1 DR. JONAS: This is a yes or no answer. Dr.
2 Goldberg, I really appreciate what is going on there. I
3 am a little skeptical about systematic reviews, having
4 done many of them, sort of like counting chad, it depends
5 on who is doing the counting and whether it has been
6 poked all the way through or not.

7 [Laughter.]

8 DR. JONAS: I have a very specific question.
9 Does your system provide acupuncture, does it make it
10 available, acupuncture, for the treatment of
11 chemotherapy-associated nausea and vomiting?

12 DR. GOLDBERG: At this moment we don't. We
13 recognize that we need to move in that direction, and it
14 is a matter of developing access and delivery systems,
15 and we are working on that right now.

16 DR. JONAS: Related to access and delivery,
17 which is what we are talking about, in the area of
18 nutritional therapy, for example, for hypertension, how
19 much time and how many visits are allowed for the
20 nutritional treatment of hypertension?

21 DR. GOLDBERG: There isn't a limit.

22 DR. JONAS: There is no limit.

1 DR. GOLDBERG: Just like how much time and how
2 many treatments are available to the physician for the
3 treatment of hypertension. They come in, they get a
4 diagnosis, they get a treatment plan, they get followed
5 up, but they may not move to the same level of
6 nutritional therapy that Dr. Gaby is talking.

7 DR. JONAS: I am sorry?

8 DR. GOLDBERG: They may or may not depending on
9 the nutritionist's treatment program. It may or may not
10 be the same level of treatment that Dr. Gaby is talking.

11 DR. JONAS: So, it will be kind of an
12 individual consultation with a nutritionist.

13 DR. GOLDBERG: Yes.

14 DR. JONAS: And it will depend on those skills
15 and that type of thing.

16 DR. GOLDBERG: Right.

17 DR. GORDON: Thank you, Wayne.

18 One thing I would like to mention to the
19 commissioners aside from apologizing to those of you we
20 couldn't include in this time, we will have time to
21 address questions of licensure, education, research, and
22 other issues in subsequent sessions.

1 I think if we can focus even more, discipline
2 ourselves to focus on access to services and service
3 delivery, that will help us move ahead, and we can ask
4 the people on this panel, if we want them back, to
5 address some of these issues, for example, how do you
6 know who an herbalist is, and how do you proceed with
7 that. We can ask them back for the panels on education
8 and licensure, et cetera.

9 So, we are going to take a break now. We will
10 return at 1:35.

11 [Lunch recess taken at 12:25 p.m.]

12 + + +
13
14
15
16
17
18
19
20
21
22

A F T E R N O O N S E S S I O N [1:35 p.m.]

Public Comment

DR. GORDON: This is the section for Public Comment. We are going to have three panels of four persons on each panel. I would like the first panel to come forward. It is Francine Butler, Nancy Dolores Kolenda, Diana Chambers, and Rustrum Roy.

Oh, we are going to get two panels together. This is our logistician here. We would like the second panel to come up. It will make life easier.

David Murray Blalwas, Kathleen Golden, Natalia Egorov, and David Edgar Molony, please.

What we will do is we will have the first four speakers and then we will have a time for questions from the commissioners, and then the next four speakers.

Each speaker in public comment time has three minutes, and we are going to be ruthless. So, we invite you to make full use of your three minutes.

First is Francine Butler.

MS. BUTLER: Thank you. Good afternoon, everyone. On behalf of the members of the Association for Applied Psychophysiology and Biofeedback, I want to

1 express thanks to the Commission for inviting us to share
2 some thinking on access, delivery, training, and
3 credentialing of CAM providers.

4 I serve as executive director of the
5 Association representing an organization that is 32 years
6 old, has 1,800 members in several disciplines. We are
7 primarily psychologists, I would say about 65 percent,
8 physicians, and nurses each represent 8 percent, social
9 workers, physical therapists, occupational therapists,
10 dentists, chiropractics represent another 12 percent, and
11 the balance are students.

12 Biofeedback is one of the most well-established
13 of the CAM therapies. The efficacy of biofeedback for
14 the treatment of specific disorders compares favorably to
15 traditional medicine. There is a large body of
16 scientific work demonstrating treatment efficacy and
17 absence of adverse side effects. Only a month ago, HCFA
18 agreed to recognize biofeedback for the treatment of
19 incontinence.

20 Nevertheless, biofeedback is not a household
21 word, nor is it an accepted word in traditional medical
22 treatment. The largest problem with access and delivery

1 that patients confront is denial by third-party payers
2 because biofeedback is still branded as experimental.

3 Individuals should not have to be forced to
4 turn to other procedures with high-risk factors when
5 biofeedback has virtually no associated risk factors for
6 treatment, nor should patients who are unable to afford
7 services be encouraged by physicians or insurance
8 companies to use medication or therapies that in some
9 cases may be less effective or simply treat the symptoms.

10 We recognize that more research is needed.
11 Like other CAM treatments, biofeedback has not been
12 provided adequate clinical research funding to conduct
13 necessary large-scale clinical outcome studies, so that
14 treatment can be evaluated as to efficacy and risk, but
15 biofeedback and other CAM applications should not have to
16 be held to higher standards than other medical protocols,
17 of bearing the proof of burden of efficacy either.

18 Access is more than just finding a
19 practitioner. It means responsible delivery of, and
20 public access to, quality information about the
21 conditions for which the treatment has efficacy.

22 It implies developing guidelines for good

1 practice management and delivery of service. It implies
2 developing a knowledge base and ensuring that
3 practitioners have met at least minimal criteria to
4 deliver treatment.

5 I am proud to say that biofeedback has met all
6 of those criteria. APB, the membership association, has
7 developed practice guidelines and standards. We have
8 prepared white papers on efficacy, and we have developed
9 consumer information brochures.

10 Most importantly, we recognize the need for
11 identifying providers, and through the Biofeedback
12 Certification Institute of America, we developed a
13 procedure for credentialing practitioners.

14 Our goal is to see that this credential be the
15 recognized standard of practice in this field.
16 Hopefully, we can be a resource to the Commission and to
17 other colleagues as they develop these areas in their
18 practice.

19 Despite these efforts, our work is not done,
20 and we are far from it. With the good officers of the
21 Commission and the NCCAM, we will have support to
22 complete the needed clinical research and remove the

1 barriers to acceptance in the third-party arena. In
2 turn, cost effective and efficacious biofeedback will
3 contribute to benefit our citizens' health and welfare.

4 Thank you.

5 DR. GORDON: Thank you very much.

6 Nancy Dolores Kolenda.

7 MS. KOLENDA: Good afternoon, everyone, and I
8 thank you for allowing me to be here and express some of
9 my ideas concerning advancing clinical research. I am
10 the director of the Center for Frontier Sciences at
11 Temple University, and in my 13 years there I have seen a
12 real revolution come about and acceptance of new
13 complementary and alternative medicine therapies.

14 The question that I raise today is what can be
15 done to expand the current research environment, so that
16 practices and interventions that lie outside conventional
17 science are adequately and appropriately addressed.

18 Well, my response to this question is the fact
19 that it is important that the major medical schools and
20 research centers throughout the United States have access
21 to funding to set up models to study various CAM
22 therapies, such as herbal medicine and homeopathy and

1 acupuncture.

2 I believe it is important for the NCCAM and the
3 firms that are related to these various therapies to make
4 this funding available to these schools and institutions.

5 The idea that I really see fourth in this is
6 that when you review the latest figures as to what is
7 being spent on CAM therapies, you can see that there are
8 firms benefiting from these investments, and they, in
9 turn, must be willing to invest in furthering the
10 research on such therapies.

11 I have really seen the importance in it right
12 now because our major medical schools I may say, speaking
13 from our own and Temple, are going through critical
14 financial crises right now in health centers, and I am
15 sure they would be more open now than ever to incentives
16 to advance the research in complementary and alternative
17 medicine therapies, and encourage that we help to find
18 that for them and make it accessible for them, and
19 stimulate them to do so.

20 I thank you.

21 DR. GORDON: Thank you.

22 Diana Chambers.

1 MS. CHAMBERS: Good afternoon. It is good to
2 be with you again.

3 Before addressing the issues of access and
4 delivery, I just want to pick up on the conversation that
5 we started in October on language and philosophy of
6 healing, because I have been thinking about it some more,
7 and we have been discussing it at length with different
8 leaders in the field what the options might be.

9 We have thought about matrix medicine or
10 multidimensional medicine, and all sorts of things, but
11 at this point, Friends of Health is recommending using
12 the phrase "whole person healing" as the phrase to best
13 describe the practices for which we are advocates.

14 "Whole person" moves us beyond the distinction
15 of mind and body, and allows for inclusion of the spirit
16 dimension, and "healing" is preferred over "medicine,"
17 the latter being so associated in many people's minds
18 with drugs or a pill.

19 We are concerned to recognize that the
20 practices for which we advocate have their own long-
21 standing foundations, and they should not be defined over
22 against conventional allopathic medicine.

1 As far as philosophy is concerned, we want to
2 recognize that in integrative medicine we have the
3 meeting of two vastly different philosophies, with
4 Western high-tech medicine focused on fixing, fighting,
5 and curing disease, while whole person healing practices
6 focus on prevention, wellness, and health.

7 Probably the greatest distinguishing factor
8 between these two philosophies can be found at the point
9 of death. While Western allopathic medicine treats death
10 as an event always to be opposed and avoided at all
11 costs, whole person healing recognizes that death is part
12 of the human experience, and it is possible, and indeed a
13 part of healing, to die well.

14 So, Friends of Health wants to ask the
15 Commission to include within its work a very careful
16 review of these issues of language and philosophy,
17 knowing that the ways in which we name practices define
18 them and affect their very nature.

19 The language of CAM is clearly limited. Many
20 of the people testifying in front of this commission have
21 evidenced their frustration with the language, and these
22 limitations need to be addressed before the practices

1 that we care about lose their essential nature because of
2 the language that we apply to them.

3 I also want to say a couple words about access
4 and delivery. Friends of Health has a particular
5 commitment to the poor and underserved population, so I
6 am delighted to have an opportunity to say a couple of
7 things for them.

8 The first question you raised was do patients
9 and health care providers have ready access to CAM
10 practices and interventions, and clearly from the
11 perspective of the poor, the answer is no.

12 The constituency with which we are concerned is
13 the poor, both urban and rural, and other than a few
14 notable exceptions, such as the wellness center at N
15 Street Village here in D.C., that offers whole person
16 healing practices to women who are in transition from
17 drug and alcohol abuse and were formerly homeless, there
18 are almost no targeted provision of such whole person
19 healing services.

20 For those without insurance and who cannot
21 afford to pay out of pocket, there is no access at all to
22 these practices, and this must be addressed both for

1 issues of equity and also that this constituency places a
2 significant burden on the public purse, which could be
3 alleviated through preventive whole person healing
4 practices. I have some ideas as to what we might do
5 about that.

6 DR. GORDON: Thank you.

7 Rustrum Roy.

8 DR. ROY: Thank you, Mr. Chairman.

9 I bring a slightly different perspective from
10 most of our colleagues here, that of a working scientist,
11 a physical scientist, 50 years on the faculty at Penn
12 State, 25 years directing its major physical science lab,
13 and deeply in the state about science today from nano
14 stuff to diamonds.

15 I am involved in the whole integrative
16 medicine, friends of whole person healing group through
17 my mentor, Linus Pauling, to my friendship with Norman
18 Cousins and Yvonne [Illich] and Chopra, and that is how I
19 have gotten into it for 25 years.

20 From that perspective, I am going to respond to
21 your questions about access. Access for whom? There are
22 three communities I want to identify, which have not been

1 touched on much. The first community is the half million
2 physicians in harness -- I am not talking about new
3 medical students -- in-harness physicians. Are they
4 being given the appropriate knowledge about whole person
5 healing?

6 The second population is academic scientists or
7 the world of science, research scientists, and the third
8 is the general attentive public, which, in theory, we
9 call the attentives.

10 The first one, how the present approaches are
11 much too small. You need real emergency education
12 program for the in-harness physicians. The consumer
13 public is going to them, and how are you going to attack
14 him? I work with Andrew Weil at the University of
15 Arizona. We take four fellows a year, and now we are
16 doing CME stuff. Maybe we will get 100, but that is
17 piddling compared to the problem.

18 So, you have got to think of an emergency, not
19 making them into alternative providers, but making them
20 into knowledgeable about and how to guide people.

21 The second population is the world of science.
22 In science, we have moved beyond all this pettiness. We

1 are in a globalized world where we take information from
2 China, from India, from anywhere. Here, we are stuck in
3 a Western model. You have to get out of that. This is
4 not the only source of truth.

5 So, if the Ayatollah is running around telling
6 people what science is, and they have had the press up
7 until now, we really have to change that attitude among
8 the scientists with information.

9 We have collected a group of the highest
10 powered world scientists, and these people will be
11 working now for the next several years on presenting to
12 show that science in the best sense is not opposed to
13 alternative medicine at all. In fact, it may very well
14 be the basis.

15 To the public I give you an example of a
16 newspaper, the Pittsburgh Post Gazette, as compared to
17 the Times or the Post or the Los Angeles Times, does a
18 wonderful job on educating its citizens in Pittsburgh
19 about the kind of stuff that alternatives do, a modest,
20 balanced presentation, so that we don't hear it
21 occasionally as some funny stuff over here, so we need
22 that.

1 Now, I have got a recommendation. I worked
2 with the President. In Reagan's administration, we had
3 zeroing out of science education. What you need, I think
4 what our country needs is whole person healing education,
5 a crash program. The Congress took it from zero to 700
6 million now, and we can have a modestly ramped-up science
7 education program, CAM education program.

8 DR. GORDON: Thank you.

9 **Panel Discussion**

10 MS. SCOTT: Thank you all for your
11 presentations. I was wondering if, Ms. Chambers, you
12 could elaborate on some of your thinking about access to
13 those communities of people who typically don't have
14 access, and include some of your recommendations for how
15 you would make sure that this population is included.

16 MS. CHAMBERS: Yes. Thank you. The question
17 that the Commission had asked was how can access to safe
18 and effective CAM practices and interventions be
19 improved. Well, for the poor, the real question is how
20 such practices can even be introduced, let alone
21 improved.

22 So, I believe that the first step is to

1 identify the most prevalent conditions that threaten the
2 health of the poor, such as obesity, heart disease,
3 diabetes, drug and alcohol abuse, and determine which
4 whole person healing practices might be most efficacious,
5 such as acupuncture for the treatment of recidivism in
6 alcoholics.

7 Then, given the culture of poverty, which is
8 the environment of the poor, I believe there must be a
9 tremendous commitment of quality resources to affect even
10 marginal change.

11 One basic step in this direction would be the
12 expansion of Medicare and Medicaid to cover whole person
13 healing practices and products with the associated
14 financial commitment to support this expansion, and then
15 if provision of whole person healing practices and
16 products for the poor were taken seriously, not only is
17 the potential for significant cost savings, and hence
18 broader provision through the release of resource, but --
19 I feel very strongly about this -- is the knowledge that
20 the poor have been treated and welcomed as whole persons,
21 a dignity that in the field of health provision, the more
22 privileged have been able to claim for themselves.

1 So, for actual delivery to the poor, speaking
2 from my personal 10-year experience of working with inner
3 city programs that are concerned with the poor, I can
4 testify to the obvious, that religious institutions offer
5 by far the most effective systems for delivery to the
6 poor of information, encouragement, and group support
7 practices.

8 These systems have been shown many times over
9 to be substantially more cost effective than federal and
10 local government initiatives, so I feel that a coherent
11 strategy for involving religious institutions in the
12 provision of whole person healing practices and products
13 should be introduced.

14 Thank you.

15 DR. GORDON: Effie.

16 DR. CHOW: Dr. Rustrum Roy, your concepts for
17 the first two was very interesting. What is your third,
18 the general --

19 DR. ROY: The general public?

20 DR. CHOW: Yes.

21 DR. ROY: In the National Science Foundation
22 where we now have \$700 million for science education,

1 remember, it was zero, it is \$700 million per year, we do
2 science literacy. That is at the level of the general
3 public, and we do also science education for making
4 scientists. Now, let's address the population of the
5 general public.

6 We need CAM literacy among the general public.
7 It is the kind of thing which the League of Women Voters
8 did a wonderful job in the seventies on educating about
9 the nuclear threat. It was very balanced, they got the
10 best advice from DOE, it was earlier in those days, and
11 we can do the same thing.

12 We can give balanced education for the general
13 public. We have an excellent model, and I propose that
14 we have a joint -- maybe the Public Health Service and
15 NSF jointly.

16 NSF has a lot of experience in doing this kind
17 of getting science knowledge out to general public, which
18 they never use, by the way, and we spent \$700 million on
19 that, and we now need CAM knowledge, so they can use it.
20 A lot of us know that wellness is going to be the most
21 cost effective. So, I would think that the model that we
22 have is existing, it is funded, I don't know, a few

1 hundred million bucks, in the NSF and the federal agency
2 to do exactly what I am talking about in the area of CAM.

3 DR. CHOW: If you have the model, is that
4 possible for you to send it in to us?

5 DR. ROY: Of course, of course, sure.

6 DR. CHOW: We would appreciate that.

7 DR. ROY: I will. Thank you.

8 DR. GORDON: Charlotte.

9 DR. LOW DOG: Dr. Roy, thank you for your
10 presentation, and all of you. I would like you to speak
11 -- you can just go off from here because I know you can
12 say a bunch of things -- about the new science, the world
13 science, and the implications for research in alternative
14 medicine.

15 DR. ROY: Well, it is not really new in a way.
16 When quantum mechanics was introduced, most of the people
17 missed the significance of it. You remember that
18 Einstein opposed it for 27 years. I have quoted him at
19 least 20 times when he opposed quantum mechanics.

20 But the real implications of quantum mechanics
21 opened the door for many of the phenomena which we see.
22 I have come back on the red eye from Honolulu to get here

1 in time for this, and we had a whole groups of presenters
2 in Honolulu on this kind of topic about saying what is
3 the model of science which permits the interaction of
4 humans with so-called dead matter, and what are the
5 models in which we can see many of the phenomena manifest
6 in Qigong practice, that we used to say, well, this is
7 all nonsense from China.

8 Well, you know, acupuncture was also labeled
9 that way. Within science, there is nothing to say then.
10 Science from Aristotle to all the great, we have said,
11 science is based on fact, not on explanations. The facts
12 are the first principles of science. I am quoting
13 [Nicho] Mccann Ethics from Aristotle.

14 So, in a very real sense, science permits us to
15 go where man has never been before, women had never been
16 before. We can go to some of these new, well-established
17 scientifically validated and empirical data in China and
18 India, and so on. We should look at them. We don't
19 stamp them and say this is okay, but we should look at
20 them.

21 DR. GORDON: Thank you.

22 Yes, Conchita.

1 DR. PAZ: This is for Francine Butler. I was
2 wondering if there is other areas besides the
3 incontinence issue that biofeedback would be real helpful
4 for.

5 MS. BUTLER: Yes, indeed, there is a whole
6 panoply of applications for which biofeedback has been
7 demonstrated effectively. Just for fun I brought our
8 notebook on white papers with us, and this is a summary
9 of probably 16 different applications, quick summaries
10 with the kinds of applications and the data used to
11 support these demonstrations.

12 DR. GORDON: Buford.

13 MR. ROLIN: This is for Ms. Chambers. You gave
14 an example of acupuncture and how it could be used. Are
15 there models or do you have any data for other models
16 that you may submit to us?

17 MS. CHAMBERS: With regard to acupuncture
18 specifically?

19 MR. ROLIN: Right, acupuncture or any of the
20 other areas that you mentioned.

21 MS. CHAMBERS: I can certainly get that
22 acupuncture materials for you. The traditional

1 Acupuncture Institute has been doing a study at -- I
2 think it is called Penn North -- Penn North in Baltimore,
3 that has shown a lot of advantages of the use of
4 acupuncture and a lot of cost savings, working with the
5 disadvantaged population, so, yes, we can get that to
6 you.

7 DR. GORDON: Buford, there are two also at
8 Hennepin County where Pat Culliton works. They have done
9 work with alcoholics, and we can ask her for that, and in
10 New York, Michael Smith will be presenting on work with
11 addicts, that he really organized.

12 There are a couple hundred programs now around
13 the United States based on his original work with
14 addicts, that I think will be interesting. We can get
15 those, as well.

16 MR. ROLIN: Thank you.

17 DR. GORDON: Any other questions?

18 DR. JONAS: I have an issue with the suggested
19 approach, Diana, that you had for approaching the whole
20 person healing. You took really what was a
21 reductionistic approach to a holistic phenomena by
22 suggesting that we look at the most common diseases and

1 then see which treatments would effectively alleviate
2 them.

3 A whole person approach, in my perspective,
4 would, in fact, look at chronic disease in general, and
5 look at ways in which health can be promoted and thus a
6 variety of conditions alleviated including improvement in
7 function and this type of thing.

8 MS. CHAMBERS: Right.

9 DR. JONAS: It is a little bit difficult to
10 then conceptualize how to deliver that in a disease-
11 oriented, trained, reimbursed health care system, so I am
12 just wondering if you had any thoughts about how that
13 might be addressed.

14 MS. CHAMBERS: I agree with you, Wayne. I
15 think I went that route because it is such an enormous
16 field and issue and concern, and to try to break it down
17 and to pick out a piece that might be doable was why I
18 had gone that route.

19 I mean I feel like nutrition is a terribly
20 important area for the poor and disadvantaged, and if we
21 could work on nutritional health -- and we were talking a
22 little bit about that this morning -- that that would

1 have a massive impact on all these other diseases that we
2 are seeing.

3 And yet I have been then thinking, okay, so how
4 do we do that. We have got to change the entire culture
5 because the poor eat at McDonald's, you know, and you are
6 not going to persuade them to go to Safeway and buy
7 vegetables, take them home and steam them. It is not
8 going to work.

9 So, that is why I had focused on a few things,
10 but I would love to see the nutritional emphasis be a
11 primary one, because I think it would have such a broad
12 effect on the whole person healing.

13 DR. JONAS: So, in that case, not focused on a
14 particular illness, but as general for health.

15 MS. CHAMBERS: Well, another way to look at it
16 would be that those other illnesses would have been
17 affected by the nutrition.

18 DR. JONAS: I had one brief question for Nancy
19 Kolenda. That is, a number of groups are now getting
20 into this field from the orthodox community, because
21 there has been some money available.

22 How can we go about sorting through which ones

1 are truly going to capture the spirit of whole person
2 health or how many are looking really at the bottom line,
3 which is getting redder and redder by the year? Is there
4 a way to approach those?

5 MS. KOLENDA: I think that there is a way to
6 approach them. I know one thing, at our medical school
7 now I am getting more questions asked about is there
8 funding for different therapies. I have two doctors up
9 at our medical school now that want to set up studies on
10 acupuncture, and I said, well, you can apply to NCCAM,
11 and they will give you guidelines on how to file for a
12 grant.

13 Our medical students particularly, they are
14 hungry for knowledge. They are upset that we don't have
15 enough elective courses, and nutrition like is one thing
16 we had a very big discussion on last month at our school
17 that it is so important, that they get so little training
18 in this, so I said that if they would do research on
19 these different issues and the importance nutrition plays
20 in overall wellness, I think we will be able to, you
21 know, address these and get their interest in it.

22 I know one thing, in fact, even I have talked

1 to two major representatives from pharmaceutical firms
2 who are also showing an interest to see what is out
3 there, and the definition they ask for is what are CAM
4 therapies, and I tell them what I know from my experience
5 and what I have read and researched to investigate, but
6 they are interested there, so I am hoping that funding
7 will come about and see the importance it will play in
8 overall health and reduce the cost of health care as a
9 whole.

10 DR. GORDON: Thank you. We will move on to the
11 next panel. David Murray Blalwas.

12 **Public Comment [Continued]**

13 DR. BLALWAS: Thank you. Good afternoon.

14 My name is David Blalwas. I am a nationally
15 board-certified licensed acupuncturist practicing in
16 Maryland. I would like to thank the Commission for this
17 opportunity to testify.

18 I am here today representing State Associations
19 of Licensed Acupuncturists from all across the country.
20 My testimony concerns two important points.

21 One. To present the Commission with data
22 concerning delivery of services and patient satisfaction

1 from a written survey of acupuncture patients conducted
2 in the State of Maryland. I have copies of the surveys
3 for the Commission's full consideration.

4 Two. In light of this evidence, to convince
5 the Commission to recommend nationwide outcomes-based
6 research studies on acupuncture and Oriental medicine as
7 performed by fully trained licensed acupuncturists, and
8 to have this research be the foundation for the formal
9 governmental recognition of acupuncture and Oriental
10 medicine as a medically effective, separate and distinct
11 system of medicine in America today.

12 The survey was created and conducted by
13 professional medical researchers. The written
14 questionnaire was designed to provide journal quality
15 outcomes-based research data on the care provided by
16 fully trained licensed acupuncturists.

17 The researchers received 1,004 completed
18 patient surveys. To our knowledge, this is the most
19 extensive acupuncture survey of patient satisfaction
20 conducted in the nation to date.

21 Here is a sample of the results from the
22 survey. When asked to rate the effectiveness of their

1 acupuncture care, 55 percent reported it very effective
2 for back pain, 49 percent reported it very effective for
3 arthritis, 54 percent reported it very effective for
4 allergies, 68 reported it very effective for stress and
5 tension.

6 When asked, "With acupuncture, do you think you
7 have been able to reduce your health care costs," 82
8 percent of patients responding said it reduced their
9 visits to medical doctors, 73 percent said it reduced
10 their use of prescription drugs, 56 percent said they
11 avoided surgery, 69 percent said it reduced coverage
12 demands from insurance companies.

13 When asked about a variety of lifestyle
14 outcomes associated with acupuncture, 56 percent strongly
15 agreed that it helped them work better, 56 percent
16 strongly agreed they have less pain, 49 percent strong
17 agreed they were less susceptible to illness.

18 When asked, "Who do you consider to be your
19 primary health care provider," 44 percent of patients
20 said medical doctor, 39 percent of patients said
21 acupuncturist.

22 This outcomes-based format we used in this

1 study makes it possible to capture the full range of
2 health benefits received by patients of acupuncture.
3 While single variable double-blind studies can provide
4 data on a single effect, acupuncture care has long been
5 known to provide simultaneous multiple physical and
6 emotional healing benefits.

7 We therefore strongly urge the Commission to
8 recommend that futures studies into the effectiveness of
9 acupuncture should take this outcome-based form. This
10 allows for the expression and evaluation of the full
11 range of health benefits patients receive from
12 acupuncture treatment.

13 Lastly, let me stress that acupuncture and
14 Oriental medicine is a separate medical system. It is a
15 form of medicine whose history, philosophical approach,
16 and treatment techniques are wholly different from
17 allopathic care. It should not be viewed as simply a
18 pain management technique that can be incorporated into
19 the Western medicine system. It is a separate medicine
20 that offers a much needed complement to the allopathic
21 model.

22 Simply put, the preventive, restorative, and

1 health maintenance medicine people receive from
2 acupuncture care is precisely what is missing from
3 American's health care system today.

4 DR. GORDON: Thank you very much.

5 Kathleen Golden.

6 MS. GOLDEN: Good afternoon and thank you for
7 having me here today. I am a licensed health care
8 provider of acupuncture and Oriental medicine in New York
9 State. I represent the Acupuncture Society of New York,
10 which is a professional organization representing the
11 interests of the practitioners and patients of New York.

12 As our focus today is access and delivery, I
13 would like to talk about an issue that I think affects
14 access and delivery for patients. Acupuncture and
15 Oriental medicine is a rich complex form of health care.
16 I feel strongly that Americans are obligated to preserve
17 the integrity and wholeness of the medicine.

18 It has been an unfortunate pattern in our
19 country to dilute the traditions of culture to suit an
20 impatient nation. I do not wish to see acupuncture and
21 Oriental medicine diluted to serve existing hierarchies
22 of health care in subsuming this medicine to augment the

1 diminishing financial returns currently experienced or to
2 boost professional all-controlling egos.

3 In this country, the acupuncture and Oriental
4 medicine profession has established national education
5 standards. These standards generally require graduation
6 from an accredited three-year Master's degree program,
7 passing a national board exam in acupuncture and/or
8 Chinese herbs, which is administered by an impartial
9 third party, and clean needle technique.

10 Completion of these standards enables a
11 provider to be licensed in their state. In many states,
12 allied health care providers are able to practice
13 acupuncture with a minimal amount of training.

14 For example, in New York, doctors, dentists,
15 and osteopaths can take a 300-hour training program in
16 acupuncture and then become certified to practice
17 acupuncture.

18 In many other states, this is also the case.
19 An unfortunate consequence of this disparity in education
20 is that the public consumer is generally unaware of the
21 differences in education and quality of care that are
22 possible.